Jane Street’s Nurix Therapeutics NRIX Stock Holding History

Jane Street’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$190K	Sell	12,273 -107,131	-90%	-$1.78M	﹤0.01%	10201
2025 Q4	$2.27M	Sell	119,404 -139,247	-54%	-$2M	﹤0.01%	4574
2025 Q3	$2.39M	Buy	+258,651	New	+$2.69M	﹤0.01%	4613
2024 Q4	–	Sell	-157,619	Closed	-$3.54M	–	10187
2024 Q3	$3.54M	Sell	157,619 -42,478	-21%	-$962K	﹤0.01%	3433
2024 Q2	$4.18M	Buy	200,097 +143,383	+253%	+$2.23M	﹤0.01%	3255
2024 Q1	$834K	Sell	56,714 -18,128	-24%	-$195K	﹤0.01%	5736
2023 Q4	$772K	Buy	74,842 +62,864	+525%	+$431K	﹤0.01%	6034
2023 Q3	$94.1K	Sell	11,978 -26,729	-69%	-$244K	﹤0.01%	7978
2023 Q2	$387K	Buy	+38,707	New	+$395K	﹤0.01%	6712
2023 Q1	–	Sell	-14,033	Closed	-$154K	–	9640
2022 Q4	$154K	Buy	+14,033	New	+$169K	﹤0.01%	7847

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Jane Street's NRIX Position: Q1 2026 in Review

Jane Street reduced its Nurix Therapeutics (NRIX) stake by 90% in Q1 2026, selling an estimated $1.78M and leaving 12,273 shares worth $190K. The position accounts for ﹤0.01% of the portfolio, ranked #10201.

Jane Street first reported a position in NRIX in Q4 2022 and has held it in 10 quarters since. The position peaked at $4.18M in Q2 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Jane Street held 12,273 shares of Nurix Therapeutics worth $190K as of Q1 2026.
Jane Street sold 107,131 Nurix Therapeutics shares in Q1 2026, an estimated $1.78M.
Nurix Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #10201 holding.
Jane Street first reported a position in Nurix Therapeutics in Q4 2022 and has held it in 10 quarters since.
Jane Street's Nurix Therapeutics position peaked at $4.18M in Q2 2024.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.